clinical trial · NCT06492291
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Merck Sharp & Dohme LLC·phase3·active not recruiting·n = 3,000
HypercholesterolemiaEnlicitide Decanoate
brief summary
This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
started
Aug 5, 2024
primary completion
Oct 13, 2028
completion
Oct 13, 2028
last updated
Oct 7, 2025
official title
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol